Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8233 ARTÍCULOS , VIENDO DEL 1306 AL 1320

Therapeutic potential of glutaminyl cyclases: Current status and emerging trends

Coimbra JRM, Moreira PI, Santos AE, Salvador JAR.

Drug Discov Today. 2023 Oct;28(10):103644. doi: 10.1016/j.drudis.2023.103644. Epub 2023 May 26.

Therapeutic Potential of Nanomedicine in Management of Alzheimer's Disease and Glioma

Anwar F, Al-Abbasi FA, Naqvi S, Sheikh RA, Alhayyani S, Asseri AH, Asar TO, Kumar V.

Int J Nanomedicine. 2023 May 22;18:2737-2756. doi: 10.2147/IJN.S405454. eCollection 2023.

COVID-19 and Alzheimer's Disease: The Link Finally Established

Fajloun Z, Wu Y, Cao Z, Kovacic H, Sabatier JM.

Infect Disord Drug Targets. 2023;23(7):14-16. doi: 10.2174/1871526523666230529162633.

Is Vitamin D Supplementation a Danger to Potential Treatments of Alzheimer's Disease Treatment?

Shih PY, Yong SB, Liu CM, Cheng-Chung Wei J.

Curr Alzheimer Res. 2023;20(2):59-62. doi: 10.2174/1567205020666230530095421.

Crosstalk between Adult Hippocampal Neurogenesis and Its Role in Alzheimer's Disease

Tiwari V, Mishra A, Singh S, Shukla S.

ACS Chem Neurosci. 2023 Jun 21;14(12):2271-2281. doi: 10.1021/acschemneuro.3c00119. Epub 2023 Jun 1.

Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer's disease? From preclinical studies to the clinical trials

Basheer N, Smolek T, Hassan I, Liu F, Iqbal K, Zilka N, Novak P.

Mol Psychiatry. 2023 Jun;28(6):2197-2214. doi: 10.1038/s41380-023-02113-z. Epub 2023 Jun 2.

Myeloid cells in vascular dementia and Alzheimer's disease: Possible therapeutic targets?

García-Culebras A, Cuartero MI, Peña-Martínez C, Moraga A, Vázquez-Reyes S, de Castro-Millán FJ, Cortes-Canteli M, Lizasoain I, Moro MÁ.

Br J Pharmacol. 2024 Mar;181(6):777-798. doi: 10.1111/bph.16159. Epub 2023 Jul 7.

CRISPR-Cas9 in Alzheimer's disease: Therapeutic trends, modalities, and challenges

Chacko L, Chaudhary A, Singh B, Dewanjee S, Kandimalla R.

Drug Discov Today. 2023 Aug;28(8):103652. doi: 10.1016/j.drudis.2023.103652. Epub 2023 Jun 7.

Targeting α7 nicotinic acetylcholine receptors and their protein interactions in Alzheimer's disease drug development

Burns LH, Pei Z, Wang HY.

Drug Dev Res. 2023 Sep;84(6):1085-1095. doi: 10.1002/ddr.22085. Epub 2023 Jun 8.

Memantine induced encephalopathy in chronic kidney disease: a case report

Prasad P, Bagai S, Khullar D.

Postgrad Med J. 2023 Jun 8;99(1171):498-499. doi: 10.1136/postgradmedj-2022-141646.

Implications of the Approval of Lecanemab for Alzheimer Disease Patient Care: Incremental Step or Paradigm Shift?

Knopman DS, Hershey L.

Neurology. 2023 Oct 3;101(14):610-620. doi: 10.1212/WNL.0000000000207438. Epub 2023 Jun 9.

Recent Mechanisms of Neurodegeneration and Photobiomodulation in the Context of Alzheimer's Disease

Su M, Nizamutdinov D, Liu H, Huang JH.

Int J Mol Sci. 2023 May 25;24(11):9272. doi: 10.3390/ijms24119272.

Advances of computer-aided drug design (CADD) in the development of anti-Azheimer's-disease drugs

Niu Y, Lin P.

Drug Discov Today. 2023 Aug;28(8):103665. doi: 10.1016/j.drudis.2023.103665. Epub 2023 Jun 9.

BACE-1 Inhibitors Targeting Alzheimer's Disease

Monteiro KLC, Dos Santos Alcântara MG, Freire NML, Brandão EM, do Nascimento VL, Dos Santos Viana LM, de Aquino TM, da Silva-Júnior EF.

Curr Alzheimer Res. 2023;20(3):131-148. doi: 10.2174/1567205020666230612155953.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias